The Alterations of Metabolic Adipo-myokines and Body Composition in End Stage Lung Cancer
The Clinical Significance of Metabolic Adipo-myokines and Alterations of Body Composition in Patients With End Stage Lung Cancer
1 other identifier
observational
600
1 country
1
Brief Summary
The investigators conduct this prospective study and wish to elucidate the association of serial change of body composition, serum adipo-myokines and adverse effect of chemotherapy and lung cancer prognosis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 2, 2023
CompletedFirst Submitted
Initial submission to the registry
September 24, 2023
CompletedFirst Posted
Study publicly available on registry
September 29, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2025
CompletedSeptember 29, 2023
September 1, 2023
2.8 years
September 24, 2023
September 24, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (13)
Number of white blood cell change among before, during and after cancer therapy
assessing the change of white blood cell count among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Percentage of body fat change among before, during and after cancer therapy
assessing the change of percentage of body fat among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Percentage of total body water change among before, during and after cancer therapy
assessing the change of total body water percentage among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Percentage of soft lean mass change among before, during and after cancer therapy
assessing the change of soft lean mass percentage among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Concentration of plasma CEA change among before, during and after cancer therapy
assessing the change of plasma CEA concentration among week 0, week 4 and week 12
week 0, week 4 and week 12 after cancer theraphy
Concentration of plasma albumin change among before, during and after cancer therapy
assessing the change of plasma albumin concentration among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Concentration of plasma myostatin change among before, during and after cancer therapy
assessing the change of plasma myostatin concentration among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Concentration of plasma FSTL-1 change among before, during and after cancer therapy
assessing the change of plasma FSTL-1 concentration among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Concentration of plasma IL-6 change among before, during and aftercancer therapy
assessing the change of plasma IL-6 concentration among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Concentration of plasma irisin change among before, during and after cancer therapy
assessing the change of plasma irisin concentration among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Concentration of plasma adiponectin change among before, during and after cancer therapy
assessing the change of plasma adiponectin concentration among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Concentration of plasma MCP-1 change among before, during and after cancer therapy
assessing the change of plasma MCP-1 concentration among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Concentration of plasma aquaporin change among before, during and after cancer therapy
assessing the change of plasma aquaporin concentration among week 0, week 4 and week 12
week 0 , week 4 and week 12 after cancer theraphy
Eligibility Criteria
All patients who diagnosed with lung cancer including small cell and non-small cell lung cancer from 2023-03-1to 2026-02-28 will be eligible for the study. Every patients' performance status must be in 0-2 and can receive any cancer treatments including chemotherapy.
You may qualify if:
- Diagnosis of lung cancer stage III to stage IV
- Adults over 20 years old
- Daily performance status of 0- 2
You may not qualify if:
- \. Cardiac stents or pacemakers
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 83301, Taiwan
Biospecimen
Adipo-myokines concentrations will be checked using residual plasma specimens on the date of before therapy, 4 weeks after therapy and 12 weeks after therapy
Study Officials
- PRINCIPAL INVESTIGATOR
TSENG CHIA-CHENG
Chang Gung Memorial Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 24, 2023
First Posted
September 29, 2023
Study Start
February 2, 2023
Primary Completion
November 30, 2025
Study Completion
November 30, 2025
Last Updated
September 29, 2023
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will not share